China Meheco Group (600056) Fundamentals 2026 — P/E 28.8x, Revenue Analysis | SniperIQ
China Meheco Group (600056) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of ¥14.1B, trading at ¥9.43 on the SHH. This SniperIQ fundamentals page covers China Meheco Group's valuation (P/E 28.8x, P/B 1.2x), profitability (net margin 1.4%), revenue (¥35.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Meheco Group's market cap?
China Meheco Group (600056) has a market capitalization of approximately ¥14.1B, trading at ¥9.43 on the SHH. Market cap moves with the live share price.
What is China Meheco Group's P/E ratio?
China Meheco Group's trailing twelve-month P/E ratio is 28.8x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Meheco Group?
China Meheco Group runs a net profit margin of 1.4%, a gross margin of 10.2%, and an operating margin of 3.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Meheco Group generate?
China Meheco Group reported revenue of ¥35.3B for fiscal year 2025, with net income of ¥473M and earnings per share (EPS) of 0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Meheco Group pay a dividend?
China Meheco Group offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China Meheco Group financially healthy?
China Meheco Group carries a debt-to-equity ratio of 0.45x and a current ratio of 1.42x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Meheco Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Meheco Group (600056) the key facts are: market cap ¥14.1B, P/E 28.8x, revenue ¥35.3B, 52-week range 8.3-12.48. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Meheco Group's full fundamentals live
Get China Meheco Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.